Ground-breaking Insights: Hereditary Angioedema Market Report Delivers Comprehensive Analysis and Future Projections by DelveInsight | CSL Behring, Ionis Pharmaceuticals, Inc., Intellia Therapeutics, KalVista Pharmaceuticals, Pharvaris Netherlands B.V.

{Delhi, India} To strategically aid Hereditary Angioedema companies developing drugs for Hereditary Angioedema, DelveInsight launched a report titled as “Hereditary Angioedema Market Insight Epidemiology and Market Forecast, 2032”. This comprehensive report delves into epidemiology based market analysis, providing a roadmap for success in the dynamic landscape of Hereditary Angioedema market.

Get a free sample of “Hereditary Angioedema Market Report”

Hereditary Angioedema Market Report’s Key Highlights:

• In 7MM, Hereditary Angioedema market size was USD 2,300 million in 2022.
• Among all the 7MM, the US consistently captured the highest Hereditary Angioedema market with nearly USD 1,900 million estimated in 2022, which is expected to grow during the forecasted period (2023-2032).
• Key Hereditary Angioedema Companies: CSL Behring, Ionis Pharmaceuticals, Inc., Intellia Therapeutics, KalVista Pharmaceuticals, Pharvaris Netherlands B.V., Astria Therapeutics, BioMarin Pharmaceutical and others.
• Key Hereditary Angioedema Therapies: Sebetralstat/KVD900, NTLA-2002, BMN 331, Garadacimab, Donidalorsen, STAR-0215, PHA121 (PHA-022121), and others.
• The diagnosed prevalent cases of HAE in the 7MM varied according to gender, with prevalent cases higher in females than males. Assessments, as per DelveInsight’s analysts, show that the overall diagnosed prevalent cases of HAE in females was 8,500, while it was 5,400 in males in 2022, these cases are subject to rise in the coming years.
• The Hereditary Angioedema market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hereditary Angioedema pipeline products will significantly revolutionize the Hereditary Angioedema market dynamics

Hereditary Angioedema Country based Treatment Analysis: 

The Hereditary Angioedema treatment market report provides treatment regimen across the 7MM. It will help companies to analyze the practices followed across 7MM, patient journey and advances in Hereditary Angioedema Therapies that have the potential to transform cancer treatment paradigms and improve patient outcomes.

Hereditary angioedema (HAE) is a rare hereditary condition that manifests as recurring incidents of localized subcutaneous (SC) or mucosal edema, most frequently affecting the skin, intestines, upper respiratory system, and oropharynx. HAE is an inherited autosomal dominant disorder conferring a 50% chance of inheritance to offspring when one of the parents is affected, although 25% of cases arise from spontaneous mutations.

Identification of defects in the SERPING1 gene and several other recently identified genes has added to the understanding of the pathophysiology of HAE significantly. HAE is classified into three types based on the problem it engenders. A person can have low levels of C1-INH in the body (Type I HAE), poorly functioning C1-INH (Type II HAE), or HAE with normal functioning C1-INH (formerly known as Type III HAE). The last type is extremely rare and poorly understood.

Download the report to understand which factors are driving Hereditary Angioedema epidemiology trends @ Hereditary Angioedema Epidemiology Forecast

 Hereditary Angioedema Epidemiology Insights: 

The report proffers historical and forecasted epidemiology insights that helps to understand the target patient population for Hereditary Angioedema. The analysis is from 2019-2032, providing insights how the patient trends are going to shape the market dynamics. Further, the epidemiology is segmented to provide in-depth analysis of patient pools allowing companies to understand their target patients pools. The epidemiology in report is segmented as : 

Hereditary Angioedema Epidemiology Segmentation:

• Total Prevalence of Hereditary Angioedema
• Prevalent Cases of Hereditary Angioedema by severity
• Gender-specific Prevalence of Hereditary Angioedema
• Diagnosed Cases of Episodic and Chronic Hereditary Angioedema

“As per the DelveInsight’s assessment, the total diagnosed prevalent cases of Hereditary Angioedema in the 7MM in 2022 was 13,900 which is expected to increase by 2032, at a considerable CAGR..”

Hereditary Angioedema Therapies and Key Companies

• Sebetralstat (KVD900): KalVista Pharmaceuticals
• NTLA-2002: Intellia Therapeutics
• BMN 331: BioMarin Pharmaceutical
• Garadacimab (CSL312): CSL Behring
• Donidalorsen (IONIS-PKK-LRx): Ionis Pharmaceuticals, Inc.
• STAR-0215: Astria Therapeutics, Inc.
• PHA-121: Pharvaris Netherlands B.V.

Emerging Hereditary Angioedema drugs Uptake:

• TAKHZYRO (lanadelumab, Takeda) is a newly-developed monoclonal antibody approved for long-term prophylaxis in HAE patients aged 12 and older. It inhibits plasma kallikrein, preventing the formation of BK and, therefore, decreasing the risk of developing angioedema. Recently, in Feb 2023, the US FDA also approved Takeda’s Takhzyro (lanadelumab-flyo) to prevent HAE attacks in children 2 years of age and older. 
• CINRYZE (Takeda) is an IV human plasma-derived C1-INH approved for patients aged 6 and older. CINRYZE requires IV administration every 3–4 days, and some patients may need higher than typical doses to achieve a reduction in attacks. 
• HAEGARDA (CSL Behring) was approved for long-term prophylaxis for adults and adolescents to fulfill this unmet need. It is a human plasma-derived C1-INH, taken twice weekly as an SC injection. HAEGARDA as a prophylaxis treatment is more effective than CINRYZE and attracted a greater number of patients due to the ease of administration.
• Potential drug targets include inhibiting factor XII (e.g., with a blocking antibody), plasma kallikrein inhibitor, inhibiting the cleavage of prekallikrein, and blocking the bradykinin-B2-receptor. Along with this, few gene therapies are developing for treating HAE; this will help treat the newly identified mutations such as FXII and PLG HAE.

To know more about Hereditary Angioedema companies working in the treatment market, visit @ Hereditary Angioedema Clinical Trials and Therapeutic Assessment

Hereditary Angioedema Market Forecast:

• The research includes a thorough analysis of the past and projected markets for Hereditary Angioedema, which includes pharmacological outreach in the 7MM nations.
• Increasing identification of a novel genetic mutation in various regions warranting further focus on the types and associated pathophysiology, including recognition of hormonal changes
• The current pipeline of Hereditary Angioedema (HAE) consists of great deal of drugs for both prophylaxis and treatment, such as Garadacimab, Donidalorsen, KVD900, NTLA-2002, and others targeting wide range of mechanism. Ongoing research and current trials have the potential to change the market. 

Discover more about therapies set to grab major Hereditary Angioedema market share @ Hereditary Angioedema Treatment Market

Scope of the Hereditary Angioedema Market Report: 

• Geography Coverage: 7MM
• Study Period: 2019-2032
• Hereditary Angioedema Market Size: ~USD 2,300 million in 2022
• Key Hereditary Angioedema Companies: CSL Behring, Ionis Pharmaceuticals, Inc., Intellia Therapeutics, KalVista Pharmaceuticals, Pharvaris Netherlands B.V., Astria Therapeutics, BioMarin Pharmaceutical and others.

Note: 

DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Hereditary Angioedema market landscape.

• Gain Competitive Edge in Indication Market : Understand the current landscape of the Hereditary Angioedema market, including the competitive environment, key companies developing drugs for Hereditary Angioedema , and their strategies. By analyzing market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.
• Identify Market Gaps and indication market opportunities : Analyzing epidemiological trends, country wise patient journeys and existing tretment practices can helps in identifying gaps and opportunities within the Hereditary Angioedema market. This involves recognizing areas where current treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing with Hereditary Angioedema. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.
• Strategic decision making : Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing - reimbursement strategies, partnerships, or other strategic moves. Understanding the market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.
• Plan RoadMap to Success : Through this report the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Hereditary Angioedema market with clarity and purpose.

Related Reports

Hereditary Angioedema Epidemiology Forecast

Hereditary Angioedema Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and Hereditary Angioedema epidemiology trends.

Hereditary Angioedema Pipeline

Hereditary Angioedema Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Hereditary Angioedema companies, including CSL Behring, Ionis Pharmaceuticals, Inc., Intellia Therapeutics, KalVista Pharmaceuticals, Pharvaris Netherlands B.V., Astria Therapeutics, BioMarin Pharmaceutical, among others.

Do you want to know how we helped our client Navigating the Asia-Pacific Life Sciences Landscape through Strategic Competitive Benchmarking: Download case study today!

 About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Ankit Nigam

Assistant Manager Marketing

Email: info@delveinsight.com

Website: https://www.delveinsight.com/consulting